Hyloris Developmentsen Sa (HYL) - Total Liabilities

Latest as of June 2025: €8.16 Million EUR ≈ $9.54 Million USD

Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has total liabilities worth €8.16 Million EUR (≈ $9.54 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Hyloris Developmentsen Sa growing its equity to track the company's year-over-year net asset growth rate.

Hyloris Developmentsen Sa - Total Liabilities Trend (2016–2024)

This chart illustrates how Hyloris Developmentsen Sa's total liabilities have evolved over time, based on quarterly financial data. See Hyloris Developmentsen Sa (HYL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Hyloris Developmentsen Sa Competitors by Total Liabilities

The table below lists competitors of Hyloris Developmentsen Sa ranked by their total liabilities.

Company Country Total Liabilities
Lucky Cement Co
TW:1108
Taiwan NT$4.41 Billion
Daewon Sanup Co. Ltd
KQ:005710
Korea ₩172.57 Billion
Canton Strategic Holdings, Inc.
NASDAQ:CNTN
USA $114.86 Million
S-Oil Corp Pref
KO:010955
Korea ₩16.34 Trillion
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
USA $10.85 Million
Nextronics Engineering
TWO:8147
Taiwan NT$866.83 Million
PetroVietnam General Services Corp
VN:PET
Vietnam ₫10.80 Trillion
Elanor Commercial Property Fund
AU:ECF
Australia AU$213.27 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Hyloris Developmentsen Sa's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HYL market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hyloris Developmentsen Sa's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hyloris Developmentsen Sa (2016–2024)

The table below shows the annual total liabilities of Hyloris Developmentsen Sa from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €9.19 Million
≈ $10.75 Million
+6.73%
2023-12-31 €8.61 Million
≈ $10.07 Million
+26.29%
2022-12-31 €6.82 Million
≈ $7.97 Million
-55.69%
2021-12-31 €15.39 Million
≈ $17.99 Million
+52.01%
2020-12-31 €10.12 Million
≈ $11.83 Million
-37.40%
2019-12-31 €16.17 Million
≈ $18.91 Million
+30.31%
2018-12-31 €12.41 Million
≈ $14.51 Million
+43.45%
2017-12-31 €8.65 Million
≈ $10.11 Million
+144.86%
2016-12-31 €3.53 Million
≈ $4.13 Million
--

About Hyloris Developmentsen Sa

BR:HYL Belgium Biotechnology
Market Cap
$154.18 Million
€131.88 Million EUR
Market Cap Rank
#17513 Global
#76 in Belgium
Share Price
€4.71
Change (1 day)
-1.46%
52-Week Range
€4.38 - €8.10
All Time High
€18.90
About

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more